Results 71 to 80 of about 907 (150)

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Cancer treatment monitoring using cell-free DNA fragmentomes

Nature Communications
AbstractCirculating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate ...
Iris van ’t Erve, Bahar Alipanahi, Keith Lumbard, Zachary L. Skidmore, Lorenzo Rinaldi, Laurel K. Millberg, Jacob Carey, Bryan Chesnick, Stephen Cristiano, Carter Portwood, Tony Wu, Erica Peters, Karen Bolhuis, Cornelis J. A. Punt, Jennifer Tom, Peter B. Bach, Nicholas C. Dracopoli, Gerrit A. Meijer, Robert B. Scharpf, Victor E. Velculescu, Remond J. A. Fijneman, Alessandro Leal   +21 more
openaire   +3 more sources

Epigenomic modifications define chromatin states to regulate cell-free DNA fragmentomics

Nature Communications
Plasma cell-free DNA (cfDNA) fragmentomics offer promising cancer biomarkers, but their molecular regulation remains elusive. Here, we investigate the role of epigenomic modifications in cfDNA fragmentation.
Fanglei Gong, Yuqi Pan, Huizhen Lin, Yunyun An, Mengqi Yang, Xiaoyi Liu, Yunxia Bai, Zhenyu Zhang, Bianbian Tang, Kun Zhang, Xin Zhao, Yu Zhao, Changzheng Du, Xuetong Shen, Kun Sun   +14 more
doaj   +1 more source

Cell‐free epigenomes enhanced fragmentomics‐based model for early detection of lung cancer

Clinical and Translational Medicine
Background Lung cancer is a leading cause of cancer mortality, highlighting the need for innovative non‐invasive early detection methods. Although cell‐free DNA (cfDNA) analysis shows promise, its sensitivity in early‐stage lung cancer patients remains a
Yadong Wang, Qiang Guo, Zhicheng Huang, Liyang Song, Fei Zhao, Tiantian Gu, Zhe Feng, Haibo Wang, Bowen Li, Daoyun Wang, Bin Zhou, Chao Guo, Yuan Xu, Yang Song, Zhibo Zheng, Zhongxing Bing, Haochen Li, Xiaoqing Yu, Ka Luk Fung, Heqing Xu, Jianhong Shi, Meng Chen, Shuai Hong, Haoxuan Jin, Shiyuan Tong, Sibo Zhu, Chen Zhu, Jinlei Song, Jing Liu, Shanqing Li, Hefei Li, Xueguang Sun, Naixin Liang   +32 more
doaj   +1 more source

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection

Nature Reviews Cancer
Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive blood-based biomarker approaches to cancer detection and disease monitoring. Current approaches for identification of circulating tumour DNA typically use targeted tumour-specific mutations or methylation analyses.
Daniel C. Bruhm, Nicholas A. Vulpescu, Zachariah H. Foda, Jillian Phallen, Robert B. Scharpf, Victor E. Velculescu   +5 more
openaire   +3 more sources

Genome-wide cfDNA fragmentation patterns in cerebrospinal fluid reflect medulloblastoma groups

npj Precision Oncology
Identifying molecular groups in medulloblastoma currently requires invasive biopsies for accurate diagnosis. We analyzed cerebrospinal fluid cell-free DNA (cfDNA) fragmentation patterns in 122 samples as a minimally-invasive alternative.
Alexander L Markowitz, Chetan Munugula, Eirini Christodoulou, Jianling Ji, Liya Xu, Jennifer A Cotter, Venkata Yellapantula   +6 more
doaj   +1 more source

Protein-oligopeptide fragmentomics

, 2008
8
openaire   +2 more sources

A method of comprehensive sequencing analysis of the small RNA fragmentome (RiboMarker)

RNA
Circulating cell-free nucleic acids (cfDNA and cfRNA) found in blood and other biofluids are promising biomarkers for cancer. However, current methods exploiting tumor-derived cfDNA (ctDNA) are not sensitive enough in detecting minimal residual disease and early stages of cancer when it is more treatable.
Rachel C. Clark, Aidan C. Manning, Jonathan M. Howard, Sergio Barberán-Soler, Sergei A. Kazakov   +4 more
openaire   +2 more sources

Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics

Journal of Experimental & Clinical Cancer Research
Background Plasma cell-free DNA (cfDNA) fragmentomics has demonstrated significant differentiation power between cancer patients and healthy individuals, but little is known in pancreatic and biliary tract cancers.
Xiaohan Shi, Shiwei Guo, Qiaonan Duan, Wei Zhang, Suizhi Gao, Wei Jing, Guojuan Jiang, Xiangyu Kong, Penghao Li, Yikai Li, Chuanqi Teng, Xiaoya Xu, Sheng Chen, Baoning Nian, Zhikuan Li, Chaoliang Zhong, Xiaolu Yang, Guangyu Zhu, Yiqi Du, Dadong Zhang, Gang Jin   +20 more
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source